至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

The nsp15 Nuclease as a Good Target to Combat SARS-CoV-2: Mechanism of Action and Its Inactivation with FDA-Approved Drugs

Microorganisms. 2022-02; 
Margarida Saramago, Vanessa G Costa, Caio S Souza, Cátia Bárria, Susana Domingues, Sandra C Viegas, Diana Lousa, Cláudio M Soares, Cecília M Arraiano, Rute G Matos
Products/Services Used Details Operation
Gene Synthesis Full-length nsp15 gene from SARS-CoV-2 (UniProt ID P0DTD1) was optimized for Escherichia coli expression and synthesized by GenScript (Piscataway, NJ, USA) Get A Quote

摘要

The pandemic caused by SARS-CoV-2 is not over yet, despite all the efforts from the scientific community. Vaccination is a crucial weapon to fight this virus; however, we still urge the development of antivirals to reduce the severity and progression of the COVID-19 disease. For that, a deep understanding of the mechanisms involved in viral replication is necessary. nsp15 is an endoribonuclease critical for the degradation of viral polyuridine sequences that activate host immune sensors. This enzyme is known as one of the major interferon antagonists from SARS-CoV-2. In this work, a biochemical characterization of SARS-CoV-2 nsp15 was performed. We saw that nsp15 is active as a hexamer, and zinc can block its a... More

关键词

FDA-approved compounds, SARS-CoV-2, inhibitors, nsp15, ribonucleases, therapeutics